March 13, 2026 a 08:38 am
BIIB: Analysts Ratings - Biogen Inc.
The stock of Biogen Inc. (BIIB) presents a mixed bag for investors, with a diverse range of ratings from analysts. Recent assessments reflect both confidence in the company's potential and a cautious approach due to market conditions. With majority of recommendations being 'Hold', the sentiment appears to be cautiously optimistic but reflects an anticipation for more concrete performance indicators. Investors should consider the company's innovative pipeline against market competition and economic variables.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 14 | |
| Hold | 20 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, Biogen has seen a significant increase in 'Hold' recommendations, indicative of analysts adopting a more reserved stance. While 'Strong Buy' recommendations have decreased, the 'Buy' category remains relatively stable, suggesting guarded optimism amid market uncertainties.
- 'Hold' ratings have risen consistently, overtaking 'Buy'.
- 'Strong Buy' recommendations have diminished, showing reduced bullish sentiment.
- Total analyst ratings have slightly increased, reflecting sustained interest but with caution.
Percentage Trends
The percentage of 'Hold' ratings has seen a marked increase, pushing aside 'Strong Buy' figures over the months. This shift highlights a trend of conservative forecasts as market conditions fluctuate.
- Decrease in 'Strong Buy' from 9% to 5% over the past 12 months.
- 'Hold' ratings surged from 11% to 20%, representing analysts' cautious stance.
- Overall ratings have increased, balanced by a noticeable tilt towards 'Hold'.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-10 | Neutral | Neutral | Wedbush |
| 2026-02-09 | Neutral | Neutral | Citigroup |
| 2026-02-09 | Neutral | Neutral | Wedbush |
| 2026-02-09 | Buy | Buy | TD Cowen |
| 2026-02-09 | Buy | Buy | HC Wainwright & Co. |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-10 | Reduce | Hold | HSBC |
| 2025-11-06 | Buy | Hold | Stifel |
| 2025-04-04 | Hold | Buy | Argus Research |
| 2025-01-02 | Neutral | Overweight | Piper Sandler |
| 2024-12-20 | Market Perform | Outperform | BMO Capital |
Interpretation
The conservative increase in 'Hold' ratings reflects a market position rife with caution, likely due to both external market pressures and company-specific considerations. The downgrade activity suggests an evaluation that leans towards cautious evaluation amid potential overvaluation concerns or competitive developments. While 'Buy' remains steady, the absence of significant 'Strong Buy' movements underlines an overall prudent forecast with varying degrees of confidence per analyst.
Conclusion
Biogen Inc.'s stock enjoys a broad spectrum of opinions, leaning towards caution with a preference for 'Hold' ratings. The sentiment has clearly shifted over recent months as analysts express prudence in light of market dynamics and competitive challenges Biogen faces in its sector. While the stable pipeline offers potential for upward revisions, uncertainties remain, warranting a balanced approach for investors. The trends highlight a period of strategic waiting as Biogen continues to develop its product lineup in acute, highly competitive therapeutic areas.